Genomics and bioinformatics are transforming diagnostic biomarker discovery and validation, offering unprecedented insights into disease molecular mechanisms. The rapid development of high-throughput technologies, specifically next-generation sequencing (NGS), has transformed cancer research by facilitating the exploration of genetic variations such as single nucleotide polymorphisms (SNPs), copy number variations (CNVs), gene expression, and protein levels. When paired with advanced computational tools, these technologies allow for the comprehensive analysis of genomic, transcriptomic, and epigenomic data at a large scale, ultimately enabling the identification of distinctive molecular signatures linked to disease conditions. Bioinformatics plays a crucial role in the management, analysis, and interpretation of this data, employing methods such as machine learning, network analysis, and integrative genomics to identify potential biomarkers with marked sensitivity and specificity. These biomarkers have the capacity to aid in prompt diagnosis, oversee the advancement of a disease, and forecast responses to treatment, ultimately enhancing patient outcomes. Moreover, bioinformatics tools assist in validating these biomarkers in various cohorts, ensuring reproducibility and reliability. These technologies have heightened the importance of precision oncology, resulting in an increased need for the identification and validation of biomarkers. This review delves into the integration of genomics and bioinformatics in biomarker discovery, emphasizing essential methodologies, challenges, and prospective paths for personalized diagnostics. Bioinformatics had a major impact on cancer research by revealing new biomarkers, driver mutations, carcinogenic pathway, and therapeutic targets. Incorporating multi-omics data, network analysis, and advanced machine learning (ML) techniques will be crucial in future biomarker discovery and prediction of patient prognosis.